Cardiovascular Health · Endothelial Function · Methylation
Your blood vessels produce a gas that keeps them open, flexible, and free from clots. After 40, production falls by roughly half. By 60, it may have fallen by 75%. Conventional cardiovascular screening doesn't measure it. Most people have never heard of it.
In 1998, Robert Furchgott, Louis Ignarro, and Ferid Murad received the Nobel Prize in Physiology or Medicine for discovering that the human body produces nitric oxide (NO) — a colourless gas — as a signalling molecule. The discovery explained why the endothelium (the single-cell lining of your blood vessels) was not just a passive barrier but an active organ producing the molecule that governs vascular tone.
Ignarro described nitric oxide as "a miracle molecule." He wasn't being hyperbolic. In the decades since, nitric oxide has been implicated in cardiovascular disease, cognitive decline, erectile dysfunction, immune dysfunction, mitochondrial energy production, and the biology of ageing. It is arguably the single most important molecule in the cardiovascular system that most people have never heard of.
Nitric oxide is produced primarily by the endothelium — the cells lining every blood vessel in your body. It diffuses into the smooth muscle cells of the vessel wall and causes them to relax, dilating the vessel and improving blood flow. This is the primary mechanism of blood pressure regulation that does not involve the kidneys or the renin-angiotensin system.
But vasodilatation is only one of its functions. The full picture:
Understanding how the body makes nitric oxide matters because different pathways fail for different reasons — and the interventions differ accordingly.
The primary endogenous route. The enzyme endothelial nitric oxide synthase (eNOS) converts the amino acid L-arginine into NO and L-citrulline. eNOS requires several cofactors to function: BH4 (tetrahydrobiopterin), NADPH, FAD, FMN, calmodulin, and molecular oxygen. When any cofactor is insufficient, eNOS becomes "uncoupled" — producing superoxide (a damaging free radical) instead of NO. This is one of the most clinically important mechanisms in endothelial dysfunction.
An alternative pathway that becomes increasingly important as eNOS function declines with age. Dietary nitrates (from leafy green vegetables, particularly beetroot, rocket, spinach, and celery) are converted to nitrite by bacteria on the tongue, then reduced to NO in the stomach and tissues. This pathway is independent of eNOS and becomes a significant supplementary source of NO in older adults and those with endothelial dysfunction.
The key clinical point: this pathway requires oral bacteria — the nitrate-reducing bacteria on the tongue. Antibacterial mouthwash use eliminates these bacteria and has been shown to meaningfully reduce NO production and raise blood pressure. This is a largely unknown mechanism by which a cosmetic product has cardiovascular consequences.
In conditions of low oxygen (hypoxia), haemoglobin, myoglobin, and cytochrome c oxidase can reduce nitrite directly to NO independent of NOS enzymes. This becomes physiologically relevant during exercise (where muscle hypoxia is local and transient) and in pathological states. It is not a primary therapeutic target but is worth understanding as part of the complete picture.
The connection between methylation and nitric oxide is direct, mechanistic, and clinically significant. It runs through three points:
BH4 synthesis is methylation-dependent. Tetrahydrobiopterin (BH4) — the critical eNOS cofactor — is synthesised from GTP through a pathway that requires adequate methylation cycle function. MTHFR impairment reduces SAM availability, which reduces BH4 synthesis. Less BH4 means eNOS uncouples — producing superoxide instead of NO.
Homocysteine accumulation destroys both NO and BH4. When the methylation cycle stalls — through MTHFR variants, B12 or folate insufficiency, or other causes — homocysteine accumulates. Homocysteine has been shown to directly scavenge NO through chemical reaction, and to generate hydrogen peroxide that oxidises BH4. The cardiovascular risk of elevated homocysteine is substantially mediated through NO depletion.
ADMA clearance requires methylation. ADMA (the eNOS inhibitor described above) is cleared by the DDAH enzyme and also by an alternative pathway requiring SAM — the methylation cycle's active methyl donor. When methylation is impaired, ADMA clearance is reduced, further inhibiting eNOS.
Homocysteine is included on the Randox Signature blood panel and is directly measurable. It is one of the most actionable cardiovascular markers on a comprehensive blood panel — and one of the most neglected in standard NHS screening.
Functional optimal range: below 7 µmol/L. NHS "normal": below 15 µmol/L (up to 20 in some labs). The difference between these thresholds matters: a homocysteine of 12 µmol/L would be reported as normal by the NHS and flagged for clinical attention by functional medicine practitioners. At 12, the endothelial damage is real and ongoing.
Homocysteine is directly toxic to the endothelial cells that produce nitric oxide, directly scavenges the nitric oxide they produce, and directly oxidises the BH4 cofactor their eNOS requires. It is attacking the system from three angles simultaneously — and it is completely addressable through B-vitamin support.
The intervention for elevated homocysteine is well established: methylfolate (5-MTHF), methylcobalamin or hydroxocobalamin, and B6 as P5P. The form of folate matters — folic acid is ineffective in MTHFR carriers and may worsen the situation through UMFA accumulation. This is directly relevant to UK folic acid fortification.
Homocysteine tells you whether methylation is adequate for NO production. hsCRP tells you whether inflammation is scavenging NO. The adhesion molecules (ICAM-1, VCAM-1, selectins) tell you whether endothelial activation is already underway — the precursor to plaque formation. D-dimer tells you whether the antithrombotic effect of NO is failing. Troponin T and NT-proBNP tell you whether cardiac muscle is being stressed. This is a complete cardiovascular picture — not a partial one.
L-arginine is widely marketed as an NO booster. The clinical evidence is more nuanced. In healthy individuals with intact eNOS, L-arginine supplementation has modest effects — the enzyme is not typically limited by substrate availability. Where L-arginine supplementation shows more consistent benefit is in conditions where eNOS is uncoupled or where ADMA is significantly elevated (competes with arginine for eNOS binding).
The more important intervention in most clinical presentations is not adding more arginine substrate — it is restoring eNOS coupling through BH4 support, reducing the ADMA that blocks it, and eliminating the oxidative stress and homocysteine that scavenge the NO that eNOS does produce. Addressing the depletion mechanisms is more effective than trying to outrun them with precursor loading.
L-citrulline is a more efficient oral precursor than L-arginine — it has higher bioavailability and is converted to arginine in the kidney without the intestinal first-pass metabolism that limits arginine absorption. If L-arginine/citrulline supplementation is being considered, L-citrulline is the better choice.
The NO literature is extensive and largely consistent on mechanisms. The intervention evidence is strongest for: aerobic exercise (robust), dietary nitrates from vegetables (good), vitamin C protection of BH4 (good mechanistic support), homocysteine reduction through B vitamins (well established). L-arginine supplementation evidence is mixed and context-dependent. I flag this because functional medicine content sometimes presents all interventions as equally evidenced — they are not. The dietary and methylation interventions have the stronger foundation.
Nitric oxide sits at the intersection of the systems that functional medicine investigates simultaneously. A client with elevated homocysteine (methylation failure), high hsCRP (inflammation scavenging NO), low omega-3 (impaired eNOS activation), elevated blood pressure (consequence of NO insufficiency), fatigue (mitochondrial function dependent on NO), and a history of poor sleep (NO production peak disrupted) is not presenting with six separate problems. They are presenting with one pattern expressing across six systems — and nitric oxide is at the centre of it.
This is precisely what comprehensive blood chemistry — read as a picture rather than a list of individual values — reveals. The Randox Signature panel gives you the homocysteine, hsCRP, adhesion molecules, and inflammatory cytokines simultaneously. The Metabolomix+ gives you the oxidative stress markers and mitochondrial function data. The DUTCH gives you the cortisol pattern (which directly inhibits eNOS). The GI-MAP gives you the gut inflammation that generates the IL-6 driving CRP that scavenges NO.
None of these panels in isolation tells the complete story. Together, they build the picture that makes the intervention precise rather than generic.
The Randox Signature blood panel includes homocysteine, hsCRP, adhesion molecules, IL-6, D-dimer, and 130–180 additional markers — giving a cardiovascular picture that a standard NHS cholesterol check cannot produce. Interpreted alongside methylation status and inflammatory patterns.
Book a conversation →